Antibody composition-producing cell in which enzyme expression is inhibited by RNAi

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7846725
APP PUB NO 20080261301A1
SERIAL NO

12060617

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, wherein the expression of GDP-mannose 4,6-dehydrogenase is inhibited by RNA interference.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
KYOWA HAKKO KIRIN CO., LTD.TOKYO280

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hanai, Nobuo Machida, JP 94 1705
Hosaka, Emi Machida, JP 45 1146
Kanda, Yutaka Machida, JP 78 1448
Nakamura, Kazuyasu Machida, JP 80 1491
Satoh, Mitsuo Machida, JP 51 1057
Shinkawa, Toyohide Machida, JP 35 1180
Uchida, Kazuhisa Machida, JP 46 1261
Yamane, Naoko Machida, JP 35 1101
Yamano, Kazuya Machida, JP 40 778
Yamasaki, Motoo Machida, JP 86 1436

Cited Art Landscape

Patent Info (Count) # Cites Year
 
CENTRO DE INMUNOLOGIA MOLECULAR (1)
5891996 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use 144 1995
 
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (1)
6238894 .alpha.1,2 fucosyltransferase 28 1999
 
PANASONIC CORPORATION OF NORTH AMERICA (2)
7687061 Method of modulating the activity of functional immune molecules to Her-2 15 2007
2007/0166,305 Method of Modulating the Activity of Functional Immune Molecules 29 2007
 
MARIEL THERAPEUTICS, INC. (1)
5614385 Methods and compositions for high protein production from recombinant DNA 34 1995
 
OSAKA UNIVERSITY (1)
2003/0170,813 Process for producing glycoprotein 33 2003
 
DOVETAIL TECHNOLOGIES INC. (1)
6762174 Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof 24 1999
 
GLAXOSMITHKLINE LLC (1)
5783184 Method for treatment and diagnosis of IL-5 mediated disorders 18 1996
 
SMITHKLINE BEECHAM P.L.C. (1)
6129913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders 28 1997
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5272070 Method for the preparation of cell lines producing Man.sub.3 GlcN.sub.ac 2 asparagine-linked gylcans and cell lines produced thereby 71 1991
 
GREEN CROSS CORPORATION, THE (1)
4721777 Process for the virus-inactivation of immunoglobulin 40 1985
 
MEDAREX, INC. (1)
5922845 Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies 113 1996
 
The University of North Carolina at Chapel Hill (1)
6350868 Antisense human fucosyltransferase sequences and methods of use thereof 26 2000
 
TOUDAI TLO, LTD. (2)
2004/0002,077 siRNA expression system and method for producing functional gene knock-down cell using the system 76 2002
2005/0048,647 Sirna expression system and process for producing functional gene knockdown cell or the like using the same 61 2004
 
Desmos, Inc. (1)
5658789 Promotion of epithelial cell adhesion and hemidesmosome assembly by a laminin-like molecule 31 1995
 
UNIVERSITY OF UTAH (1)
5464764 Positive-negative selection methods and vectors 270 1993
 
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (2)
5977316 Monoclonal antibody 1A7 and related polypeptides 34 1996
5935821 Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma 49 1996
 
WISTAR INSTITUTE, THE, A CORP OF PA (1)
4849509 Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies 53 1987
 
CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY (1)
6540980 Method of detecting endometriosis 30 2000
 
Hazleton Biotechnologies, Inc. (1)
4757018 Myeloma cell lines and uses thereof 31 1985
 
ROCHE GLYCART AG (5)
6602684 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 175 1999
2004/0072,290 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 72 2003
2005/0074,843 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 51 2003
2005/0079,605 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity 47 2003
2007/0111,281 Antigen binding molecules having modified Fc regions and altered binding to Fc receptors 40 2006
 
THERMO FISHER SCIENTIFIC INC. (1)
2007/0031,844 Functional and hyperfunctional siRNA 425 2003
 
ACTIVCARD IRELAND LIMITED (1)
7502497 Method and system for extracting an area of interest from within an image of a biological surface 20 2007
 
MILLENNIUM PHARMACEUTICALS, INC. (2)
6488930 Anti-CCR4 antibodies and methods of use therefor 37 1999
7138117 Anti-CCR4 antibodies and methods of use therefor 25 2002
 
ICOS Corporation (3)
5880268 Modulators of the interaction between ICAM-R and .alpha..sub.d /CD18 38 1995
5932703 Macrophage derived chemokine and chemokine analogs 38 1996
6498015 Methods of identifying agents that modulate the binding between MDC and an MDC receptor 33 1997
 
THE GENERAL HOSPITAL CORPORATION (1)
5858983 Inhibition of cell adhesion protein-carbohydrate interactions 46 1995
 
FUJITSU LIMITED (1)
6189781 Terminal unit having function for converting commodity information into bar code and vice versa 34 1994
 
CHUGAI SEIYAKU KABUSHIKI KAISHA (1)
2003/0190,316 Stabilized antibody-containing preparations 92 2003
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
4350683 Antibody production from hybrid cell line 85 1980
 
GLAXO GROUP LIMITED (1)
6150132 Chemokine receptor able to bind to MCP-1, MIP-1.alpha. and/or RANTES. Its uses 43 1997
 
KYOWA HAKKO KOGYO CO., LTD. (5)
2004/0093,621 Antibody composition which specifically binds to CD20 107 2002
2004/0110,704 Cells of which genome is modified 75 2003
2005/0160,485 Mouse in which genome is modified 24 2004
2005/0226,867 IL-5R-specific antibody composition 26 2004
2005/0287,138 CCR4-specific antibody composition 26 2004
 
LEUKOSITE, INC. (1)
6245332 Modulation of systemic memory T cell trafficking 33 1999
 
KYOWA HAKKO KIRIN CO., LTD. (36)
5830470 Humanized antibodies to ganglioside GM.sub.2 52 1993
6018032 Antibody against human interleukin-5-receptor .alpha. chain 44 1997
6437098 Human chimeric antibody specific for the ganglioside GD3 28 1999
6986890 Anti-human VEGF receptor Flt-1 monoclonal antibody 45 1999
6989145 Recombinant antibody and antibody fragment 40 2001
6946292 Cells producing antibody compositions with increased antibody dependent cytotoxic activity 113 2001
2003/0175,273 Human CDR-grafted antibody and antibody fragment thereof 35 2002
7691568 Antibody composition-containing medicament 15 2003
2004/0110,282 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost 51 2003
2004/0132,140 Production process for antibody composition 106 2003
7691810 Method of producing recombinant antithrombin III composition 12 2004
2005/0187,380 Method for treating Th2-mediated disease 24 2005
7214775 Method of modulating the activity of functional immune molecules 78 2005
7708992 Methods for producing antibody compositions with increased ADCC 20 2005
2005/0272,916 Method of modulating the activity of functional immune molecules 40 2005
2006/0024,800 Method of modulating the activity of functional immune molecules 33 2005
2005/0216,958 Cells of which genome is modified 28 2005
2005/0262,593 Antibody composition-producing cell 31 2005
2006/0223,147 Process for producing glycoprotein composition 37 2005
2006/0063,254 Antibody composition-producing cell 39 2005
2006/0064,781 Antibody composition-producing cell 38 2005
7393683 Mammalian host cell modified by RNAi to inhibit .alpha. 1,6-fucosyltransferase 23 2005
7425446 Antibody composition-producing cell 28 2005
7709234 α-1,3-fucosyltransferase 13 2006
2007/0148,165 Recombinant antibody composition 24 2006
7651688 Method of modulating the activity of functional immune molecules to CD52 18 2007
7655228 Method of modulating the activity of functional immune molecules to GM2 15 2007
7682610 Method of modulating the activity of functional immune molecules 15 2007
7682611 Method of modulating the activity of functional immune molecules to CXCR4 protein 15 2007
7708997 Method of modulating the activity of functional immune molecules 15 2007
2007/0166,300 Method of Modulating the Activity of Functional Immune Molecules 28 2007
2007/0166,301 Method of Modulating the Activity of Functional Immune Molecules 28 2007
2007/0166,302 Method of Modulating the Activity of Functional Immune Molecules 28 2007
2007/0166,303 Method of Modulating the Activity of Functional Immune Molecules 28 2007
2007/0166,304 Method of Modulating the Activity of Functional Immune Molecules 28 2007
2008/0261,301 Antibody Composition-Producing Cell 26 2008
 
TANIGUCHI, NAOYUKI (2)
6054304 .alpha.1-6 fucosyltransferase 51 1998
6291219 .alpha.1-6 fucosyltransferase 24 1999
 
BIOGEN IDEC MA INC. (1)
7033589 γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics 26 1999
 
GeneNews Inc. (1)
2005/0208,519 Biomarkers for diagnosing schizophrenia and bipolar disorder 17 2004
 
Genentech, Inc. (4)
4816567 Recombinant immunoglobin preparations 2225 1983
6169070 Mer receptor activation by gas6 78 1996
6737056 Polypeptide variants with altered effector function 361 2000
7297775 Polypeptide variants 50 2002
 
BIOGEN, INC. (1)
6455043 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody 112 1999
 
TAKATSU, KIYOSHI (1)
5916767 DNA encoding human interleukin-5 receptor 14 1997
 
SRD PHARMACEUTICALS, INC. (1)
5665569 HIV immunotherapeutics 44 1994
 
BOEHRINGER MANNHEIM GMBH (1)
5453363 Process for the activation of t-PA or Ing after genetic expression in prokaryotes 37 1994
 
LONZA GROUP AG (1)
5672502 Animal cell culture 81 1995
 
GENETICS INSTITUTE, LLC (1)
5728568 Human GDP-mannose 4,6 dehydratase 32 1996
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
BIOWA, INC. (1)
8501176 Methods of reducing eosinophil levels 3 2011
 
KYOWA HAKKO KIRIN CO., LTD. (15)
8067232 Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase 0 2008
* 2008/0227,196 Antibody Composition-Producing Cell 5 2008
8158760 Glycoengineered, recombinant antibody 1 2009
8039595 Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation 5 2009
8367407 Cells with altered fucosylation and producing antibodies therefrom 0 2009
* 2010/0143,388 Antibody Composition-Producing Cell 4 2009
8679491 Method of modulating the activity of functional immune molecules 1 2009
* 2011/0027,271 ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION 4 2010
8110195 Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody 1 2010
* 8101185 Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation 1 2010
* 8329443 Antibody composition-producing cell 1 2011
* 2011/0250,643 ANTIBODY COMPOSITION-PRODUCING CELL 6 2011
8895266 Antibody composition-producing cell 1 2012
9637545 Method of modulating the activity of functional immune molecules 0 2014
9409982 Antibody composition-producing cell 0 2014
 
ASTRAZENECA AB (3)
9441037 Methods for reducing exacerbation rates of asthma using benralizumab 0 2014
9441046 Methods for increasing forced expiratory volume in asthmatics using benralizumab 0 2014
9441047 Methods for improving asthma symptoms using benralizumab 0 2014
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 7, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 7, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00